APA (7th ed.) Citation

Tim A. Kanters, Jelena Stevanovic, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, & Steven Simoens. (2017). Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Tim A. Kanters, Jelena Stevanovic, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, and Steven Simoens. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers Media S.A., 2017.

MLA (9th ed.) Citation

Tim A. Kanters, et al. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers Media S.A., 2017.